Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Geron Corporation GERN
$3.04
+$0.15 (5.02%)
На 18:00, 12 мая 2023
+64.47%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1544001620.00000000
-
week52high
3.84
-
week52low
1.18
-
Revenue
596000
-
P/E TTM
-8
-
Beta
0.90830400
-
EPS
-0.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 22 авг 2022 г. |
| Needham | Buy | Buy | 12 авг 2022 г. |
| Needham | Buy | Buy | 10 мая 2022 г. |
| Baird | Outperform | 02 ноя 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 26 авг 2020 г. |
| Wedbush | Outperform | 28 окт 2022 г. | |
| Needham | Buy | Buy | 09 янв 2023 г. |
| Wedbush | Outperform | Outperform | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| EASTHAM KARIN | D | 0 | 35000 | 13 янв 2023 г. |
| EASTHAM KARIN | A | 109047 | 35000 | 13 янв 2023 г. |
| Spiegel Robert J. | A | 151693 | 2970 | 30 дек 2022 г. |
| Kapur Anil | A | 53216 | 6021 | 30 дек 2022 г. |
| Spiegel Robert J. | A | 148723 | 3071 | 30 сент 2022 г. |
| GRETHLEIN ANDREW J | D | 0 | 232719 | 12 сент 2022 г. |
| GRETHLEIN ANDREW J | D | 65281 | 2000 | 12 сент 2022 г. |
| GRETHLEIN ANDREW J | A | 234719 | 232719 | 12 сент 2022 г. |
| GRETHLEIN ANDREW J | A | 2000 | 2000 | 12 сент 2022 г. |
| McDonald John F | A | 200000 | 200000 | 07 сент 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8796510 | -85650 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 3971340 | 113696 | 31 авг 2020 г. |
| iShares NASDAQ Biotechnology ETF | 3135460 | -59483 | 31 авг 2020 г. |
| iShares Russell 2000 Value ETF | 1640360 | 18864 | 31 авг 2020 г. |
| Schwab U.S. Small-Cap ETF | 1125740 | 4378 | 31 авг 2020 г. |
| Vanguard Health Care Index Fund | 846666 | 0 | 31 авг 2020 г. |
| Fidelity Select Biotechnology Portfolio | 9109440 | -3370100 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 4269790 | -10068 | 31 июл 2020 г. |
| Fidelity Extended Market Index Fund | 1512980 | 0 | 31 июл 2020 г. |
| Fidelity Small Cap Index Fund | 1096170 | 125533 | 30 апр 2020 г. |
Новостная лента
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Business Wire
11 мая 2023 г. в 10:02
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually. The three EHA abstracts on IMerge Phase 3 data expand upon and further confirm the differentiating qualities of imetelstat that ca.
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
Business Wire
04 мая 2023 г. в 16:30
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern Time via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results, as well as business highlights and upcoming milestones, at 10:30 a.m. Eastern Time t.
Why Shares of Geron Are Up 30% This Week
The Motley Fool
20 апр 2023 г. в 12:18
Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications.
Geron to Present at Upcoming Investor Conferences in April
Business Wire
12 апр 2023 г. в 16:40
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences: 22nd Annual Needham Virtual Healthcare Conference Thursday, April 20 at 10:15 a.m. ET Stifel 2023 Virtual Targeted Oncology Days Tuesday, April 25 at 2:00 p.m.
Geron Corporation (GERN) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 20:53
Geron Corporation (NASDAQ:GERN ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman and Chief Executive Officer Olivia Bloom - Executive Vice President and Chief Financial Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Conference Call Participants Kalpit Patel - B. Riley Stephen Willey - Stifel Joel Beatty - Baird Gil Blum - Needham Operator Good afternoon.